Double-Blind, Randomized, Phase 2a Study to Evaluate the Safety and Immunogenicity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, Co-Administered with Fluarix Tetra® or Afluria Quad®
Background/Objectives: For decades, influenza vaccine development has focused on eliciting antibody responses. Increasing evidence suggests that cell-mediated immune (CMI) responses can complement the humoral response by providing broader protection. This study evaluated the safety and immunogenicity of an experimental...